A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease on Donepezil

Study Status: 
Closed
Study Description: 

This is a Phase 3, safety and efficacy study of Dimebon for the treatment of Alzheimer's disease. Study participants are asked to come for study-related visits 10 times during a 1-year period, take study medications as directed by study personnel, and complete all study-related procedures.

 

ELIGIBILITY CRITERIA

 

Inclusion criteria:

1. Have mild to moderate Alzheimer's disease.

2. Be 50 years of age or older.

3. Have been taking Aricept (Donepezil) for at least 6 months.

4. Have a caregiver who assists (or directly supervises) the participant at least 5 days per week for at least 3 hours a day.

5. Living in the community and may be living in an assisted-care facility if living independently.

 

More information about the study may be found on the attached document.

Study Coordinator(s): 

Martha Vander Vliet, RN

Tel:  617-732-8085

AttachmentSize
mcginnis2009P000934webadame7.pdf292.52 KB